GATAD2B Antibody, Biotin conjugated

Code CSB-PA823905LD01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) GATAD2B Polyclonal antibody
Uniprot No.
Target Names
GATAD2B
Alternative Names
FLJ37346 antibody; GATA zinc finger domain containing 2B antibody; GATA zinc finger domain containing protein 2B antibody; GATA zinc finger domain-containing protein 2B antibody; GATAD2B antibody; KIAA1150 antibody; MGC138257 antibody; MGC138285 antibody; mKIAA1150 antibody; p66/p68 antibody; P66B_HUMAN antibody; P66beta antibody; RGD1308533 antibody; transcription repressor p66 beta component of the MeCP1 complex antibody; Transcriptional repressor p66 beta antibody; Transcriptional repressor p66-beta antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Transcriptional repressor p66-beta protein (58-146AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Biotin
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Transcriptional repressor. Enhances MBD2-mediated repression. Efficient repression requires the presence of GATAD2A. Targets MBD3 to discrete loci in the nucleus. May play a role in synapse development.
Gene References into Functions
  1. GATAD2B interacts with C-MYC to enhance KRAS driven tumor growth. PMID: 30013058
  2. This data suggests that 1q21.3 microdeletion is a recurrent microdeletion syndrome with distinguishable phenotypes, and loss of function of GATAD2B is the major contributor of the characteristic facies and ID. PMID: 28211977
  3. findings suggest that GATAD2B serves as an important mediator of progesterone-progesterone receptor suppression of proinflammatory and contractile genes during pregnancy; decreased GATAD2B expression near term may contribute to the decline in progesterone receptor function, leading to labor PMID: 28576827
  4. This is the first report of GATAD2B in Chinese ID patients. Our findings will broaden the spectrum of GATAD2B mutations and facilitate genetic diagnosis and counseling. PMID: 28077840
  5. p66beta might be important for the regulation of LOX in the nucleus. PMID: 25118846
  6. Detailed clinical description showed that all four individuals with a GATAD2B aberration had a distinctive phenotype with childhood hypotonia, severe intellectual disability. PMID: 23644463
  7. identification as potent transcriptional repressors interacting with MBD2 and MBD3 PMID: 12183469

Show More

Hide All

Involvement in disease
Mental retardation, autosomal dominant 18 (MRD18)
Subcellular Location
Nucleus speckle.
Tissue Specificity
Widely expressed.
Database Links

HGNC: 30778

OMIM: 614998

KEGG: hsa:57459

STRING: 9606.ENSP00000357644

UniGene: Hs.4779

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*